Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HHS Should Encourage Prospective Outcome Studies of Pharmacogenetic Drug Dosing, SACGHS Says

This article was originally published in The Pink Sheet Daily

Executive Summary

One example of the value of genotyping is Genentech's Herceptin, committee members agreed.

You may also be interested in...



FDA Signs Cooperative Agreement To Develop Standards For Warfarin-Dosing Biomarkers

The Critical Path Institute, in conjunction with the University of Utah, will be awarded $750,000 in funding by FDA to be used, in part, to validate and standardize genetic testing for biomarkers related to warfarin efficacy and metabolism.

FTC Suffers Reversal On “Reverse Payments” Enforcement

The Solicitor General says the Supreme Court should not hear the Commission's appeal of a case brought against Schering-Plough regarding a generic drug settlement.

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel